Recombinant DNA Technology Market Expected to Expand at a Steady 2021-2028 | Thermo Fisher Scientific, Inc., Biogen, Inc.

Overview:

Recombinant DNA technology involves joining of two DNA molecules from two different species. It allows transfer of preferred specific characteristics, which helps to improve pre-existing systems and controls expression of target genes. Mass production of therapeutic proteins characterized by higher consistency and stability. Access to a wide array of approved recombinant therapeutics, increased number of CAR-T gene therapies and presence of new gene editing techniques based on rDNA are expected to boost growth of the recombinant DNA technology market during the forecast time.

Global Recombinant DNA Technology Market, was valued at US$ 106.8 Billion in 2017 and is expected to exhibit a CAGR of 7.9% over the forecast period (2017 – 2025).

Request Here For Market Latest Insights(PDF): https://www.coherentmarketinsights.com/insight/request-pdf/893

Drivers:

Frequent approvals and launches of new recombinant products are expected to propel growth of the global recombinant DNA technology market. For instance, in 2015, GlaxoSmithKline Plc., received an approval of the U.S. FDA for its Nucala (mepolizumab), a humanized interleukin-5 antagonist monoclonal antibody developed with recombinant DNA technology for the treatment of acute asthma.

Moreover, in 2016, the U.S. FDA approved CSL Behring’s Idelvion, Coagulation Factor IX, albumin fusion protein developed with recombinant DNA technology for treating Hemophilia B in children and adults.

Similarly, in 2017, the U.S. FDA granted approval to Kymriah (tisagenlecleucel) of Novartis AG. Kymriah is the first ever chimeric antigen receptor T cell therapy developed for treating severe lymphoblastic leukemia.

Increasing research activities to develop and introduce new treatments based on gene editing techniques for cancer therapies and sickle cell anemia treatment are expected to drive growth of the global recombinant DNA technology market. For instance, in 2016, a team of scientists from the Columbia University Medical Center (CUMC) and University of Iowa developed a technique to repair a genetic mutation that causes retinitis pigmentosa (RP) with CRISPR.

In January 2018, scientists at University of Pennsylvania developed a cancer therapy based on CRISPR, which was approved by the U.S. FDA and the National Institutes of Health for the first CRISPR human trial to treat sarcoma, multiple myeloma and melanoma.

Key Takeaways:

Global Recombinant DNA Technology Market, was valued at US$ 106.8 Billion in 2017 and is expected to exhibit a CAGR of 7.9% over the forecast period (2017 – 2025).

Purchase this Report - https://www.coherentmarketinsights.com/insight/buy-now/893

Recombinant therapeutic proteins sector is expected witness a strong growth in the recombinant DNA technology market, due to availability of wide range of products for the treatment of various diseases such as cancer, asthma, hemopilia and diabetes.

Therapeutic sector is expected to witness robust growth in the market of recombinant DNA technology. This is attributed to increasing genetically engineered products like erythropoietin, novel gene therapies and recombinant insulin for treating different diseases.

Recombinant DNA Technology Market – Competitive Landscape

Key players functioning in the global prosthetic liners market consists of Thermo Fisher Scientific, Inc., Biogen, Inc., Sanofi Pasteur, Merck & Co., Inc., Pfizer, Inc., Profacgen, Amgen, Inc., and Monsanto Company

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Other Reports:

Photoplethysmography (PPG) Biosensors Market - https://www.coherentmarketinsights.com/press-release/photoplethysmography-biosensors-market-3892

Deep Brain Stimulation Devices Market - https://www.coherentmarketinsights.com/press-release/deep-brain-stimulation-devices-market-for-parkinsons-disease-3879

This release was published on openPR.